Clinical and diagnostic management of toxoplasmosis in the immunocompromised patient.
about
Protective immunity against toxoplasmosis in mice induced by single-dose immunization with rSAG1/2 protein released from poly(lactide-co-glycolide) microparticlesPrenatal diagnosis and prevention of toxoplasmosis in pregnant women in Northern Vietnam: study protocolImportance of nonenteric protozoan infections in immunocompromised people.Utility of molecular and serodiagnostic tools in cerebral toxoplasmosis with and without tuberculous meningitis in AIDS patients: A study from South India.Plasma microRNAs are promising novel biomarkers for the early detection of Toxoplasma gondii infection.Toxoplasmic encephalitis in an AIDS cohort at Puerto Rico before and after highly active antiretroviral therapy (HAART)Molecular and serological detection of acute and latent toxoplasmosis using real-time PCR and ELISA techniques in blood donors of rafsanjan city, iran, 2013Toxoplasmosis: a global threat.Type II Toxoplasma gondii KU80 knockout strains enable functional analysis of genes required for cyst development and latent infection.Deciphering the Draft Genome of Toxoplasma gondii RH Strain.High Seroprevalence of Toxoplasma gondii Antibody in HIV/AIDS Individuals from North of Iran.Induction of long-lasting protective immunity against Toxoplasma gondii in BALB/c mice by recombinant surface antigen 1 protein encapsulated in poly (lactide-co-glycolide) microparticles.The Toxoplasma gondii Rhoptry Kinome Is Essential for Chronic Infection.Successful Treatment of Pulmonary and Cerebral Toxoplasmosis Associated with Pneumocystis Pneumonia in an HIV Patient.The Expressed MicroRNA-mRNA Interactions of Toxoplasma gondii.Synthesis, molecular docking, ctDNA interaction, DFT calculation and evaluation of antiproliferative and anti-Toxoplasma gondii activities of 2,4-diaminotriazine-thiazole derivatives.
P2860
Q28846409-9DDA315A-83C6-42E3-BA92-DCAB2E917542Q30376785-56F2CBB6-4429-49F2-B5B8-681E792786DBQ34189873-1D9640FA-6B5C-4511-9DC7-B1619E5188EBQ34495782-9FD9E000-F8CC-4C2C-B0CA-ADFFE8361701Q34667389-33F23804-68AA-4CAF-BBFF-6C60B5D92CA3Q34875897-55446BF0-475C-4FE5-9E79-D3A918B2DF44Q35047324-9F1EAD03-9810-4BEA-9465-96A467680DCBQ35183980-EE4C9EFB-14E8-4F29-967C-776E5A96C4A1Q35271230-C9749F02-DC61-4971-B838-251187D47B9BQ36063882-84040799-5BD3-4850-B86B-46C4A46A70F2Q36495972-24315E87-41C2-4DC7-B91D-F20E4A703A1CQ36646902-056DE977-0D8C-4FB6-8BF5-FA5CCD72F66CQ37123452-84BBE2DE-463F-43CC-92FD-92F905CBCB84Q47229986-01B7E706-4300-4B75-9850-17708D15867BQ49727586-851BDDDC-D4CC-4991-906F-B8CE5241E3D9Q52342512-1CBE7ADF-0018-45E4-85DF-19D07502052A
P2860
Clinical and diagnostic management of toxoplasmosis in the immunocompromised patient.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Clinical and diagnostic management of toxoplasmosis in the immunocompromised patient.
@en
Clinical and diagnostic management of toxoplasmosis in the immunocompromised patient.
@nl
type
label
Clinical and diagnostic management of toxoplasmosis in the immunocompromised patient.
@en
Clinical and diagnostic management of toxoplasmosis in the immunocompromised patient.
@nl
prefLabel
Clinical and diagnostic management of toxoplasmosis in the immunocompromised patient.
@en
Clinical and diagnostic management of toxoplasmosis in the immunocompromised patient.
@nl
P921
P1433
P1476
Clinical and diagnostic management of toxoplasmosis in the immunocompromised patient.
@en
P2093
P577
2008-06-01T00:00:00Z